This page shows the latest Vizimpro news and features for those working in and with pharma, biotech and healthcare.
Takes fight to Pfizer's Vizimpro. AstraZeneca has the improvement in overall survival (OS) it needed for lung cancer therapy Tagrisso (osimertinib), as it tries to double down on its use ... NICE also judged that the drug would not eligible for inclusion
The decision not to recommend Tagrisso coincided with NICE’s recommendation of Pfizer’s Vizimpro (dacomitinib) in the same patient population. ... However, NICE did acknowledge that Vizimpro had a higher incidence of side effects, so a lower dose
Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro (dacomitinib) for locally advanced or metastatic EGFR-positive non-small cell lung cancer (NSCLC).
That includes Xalkori follow-up Lorbrena (lorlatinib) for ALK-positive non-small cell lung cancer (NSCLC), PARP inhibitor Talzenna (talazoparib) for breast cancer, Daurismo (glasdegib) for acute myeloid leukaemia, and Vizimpro
That will come on the back of product launches like tafamidis in rare disease transthyretin amyloid cardiomyopathy, a trio of recently-approved cancer drugs including Vizimpro (dacomitinib), a rival to
Five year survival still only 12%. Pfizer’s Vizimpro, a drug that could challenge AstraZeneca’s fast-growing Tagrisso in lung cancer, has been approved for marketing by the European Commission. ... Vizimpro (dacomitinib) has been approved in the EU
More from news
Approximately 5 fully matching, plus 5 partially matching documents found.
In its 2019 reviews of Pfizer’s Vizimpro and Takeda’s Adcetris, NICE noted that EQ-5D “may not be sensitive to skin-related diseases” and may fail to fully capture
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...